NYSE:NSPR
InspireMD Inc Stock News
$2.00
-0.0100 (-0.498%)
At Close: May 03, 2024
NSPR Stock: 1-For-15 Reverse Stock Split
04:57am, Tuesday, 27'th Apr 2021
InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB) recently announced a 1-for-15 reverse split of its common stock, effective as of yesterday. These are the details.
InspireMD Provides Corporate Update for Shareholders
06:00am, Monday, 19'th Apr 2021
TEL AVIV, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke c
InspireMD Announces 1-for-15 Reverse Stock Split
04:05pm, Wednesday, 14'th Apr 2021
TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke c
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
06:30am, Tuesday, 09'th Mar 2021
Management to host investor conference call today, March 9, at 8:30am ET Management to host investor conference call today, March 9, at 8:30am ET
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
06:00am, Tuesday, 02'nd Mar 2021
Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
06:00am, Wednesday, 24'th Feb 2021
TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid art
TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid art
InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
04:05pm, Monday, 08'th Feb 2021
TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent p
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
08:30am, Thursday, 04'th Feb 2021
TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent p
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
08:32am, Wednesday, 03'rd Feb 2021
New Chinese Distributor Will Also Invest in At-The-Market Private Placement New Chinese Distributor Will Also Invest in At-The-Market Private Placement
TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript
12:40pm, Monday, 09'th Nov 2020
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke c
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke c
InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update
06:30am, Monday, 02'nd Nov 2020
Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET
